

Newpath Partners Closes \$350M Second Fund

Client News

December 8, 2021

Gunderson Dettmer represented venture firm Newpath Partners in the formation of its \$350 million second fund, Newpath Partners II. With this fund, Newpath will continue its mission of partnering with leading scientific entrepreneurs to develop transformational therapies for complex diseases.

“Our team at Newpath Partners is guided by a simple ethos – do the right thing and good things will happen. This principle has attracted the continued support of our investors and bold ideas from leading scientists. Many of these ideas are now advancing through portfolio companies to drive solutions for the world’s greatest medical challenges,” said Thomas Cahill MD, PhD, founding partner of Newpath Partners.

The Gunderson deal team was led by Malcolm Nicholls and included Emily O’Brien, Blake Rowe and Gabrielle Paradis.

Newpath Partners

Related People





Malcolm B. Nicholls, III

PARTNER

P +1 617 648 9170



Emily P. O'Brien

PARTNER

P +1 617 648 9321



Blake Rowe

ASSOCIATE

P +1 617 648 9309

Related Services

Fund Formation

Private Fund

Featured Insights

PUBLIC VENTURES

Trump Executive Order Targets Proxy Advisors Over DEI and ESG Influence

EVENTS

Webinar: Paradigm Shift? Mandatory Securities Arbitration and the Impact of the SEC's Recent Policy Statement for Companies and Investors

FIRM NEWS

Amidst Strong Year, Gunderson Dettmer Elects Nine New Partners

EVENTS

Webinar: AI in the Workplace: Legal Challenges and Best Practices

FIRM NEWS

2025 CVCA Annual General Meeting & Private/Venture Capital Summit in Beijing

CLIENT NEWS

Gunderson Dettmer Represented Hims & Hers in Acquisition of Livewell

CLIENT NEWS

Replicate Bioscience Announces Collaborative Agreement with Instituto Butantan

CLIENT NEWS

Gunderson Client Neptune to Be Acquired by OpenAI

CLIENT NEWS

Hims & Hers Announces Definitive Agreement to Acquire YourBio Health

CLIENT NEWS

LotusFlare Announces Equity Investment from Ericsson

PUBLIC VENTURES

SEC Chair Charts Disclosure Overhaul to Revive IPOs: Materiality and Scale Over 'Regulatory Creep'

CLIENT NEWS

Vambe Raises \$14M Series A Led by Monashees